BPLPHARMABharat Parenterals

₹1222.45+0.00%

Market Cap

₹842.51 Cr

Stock P/E

-148.59

ROCE

-4.85%

ROE

-16.55%

Book Value

₹478.53

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
FY25 standalone revenue growth with improving profitability (revenue +19.8%, PAT +17%), margins stable.
•
Innoxel achieved US FDA inspection with minimal observations, signaling regulatory credibility.

NEGATIVES

•
Regulatory/licensing timing risk for Innoxel (licensing/CMO revenue realization uncertain and depends on partner filings).
•
Near-term funding risk: significant debt with no current plan to raise new funds.

Peers Summary

Sector Leader

Bharat Parenterals Ltd. exhibits promising growth metrics but struggles with profitability compared to its peers, which are predominantly more established. Companies like Cipla and Dr. Reddy's lead in profitability, while Bharat Parenterals may represent a growth opportunity at a reasonable valuation despite its current financial challenges.

Key Points

• Bharat Parenterals shows significant revenue growth but has negative EPS, indicating potential for improvement.
• Cipla and Dr. Reddy's have superior profitability metrics and low valuation ratios, making them attractive investments.
• Bharat Parenterals' debt levels are manageable, suggesting financial stability compared to more leveraged peers.

Top Performers

Cipla Ltd.

Strong profitability with a low PE ratio and high ROE.

Dr. Reddy's Laboratories Ltd.

Excellent profitability metrics with low valuation ratios.

Mankind Pharma Ltd.

High growth metrics and strong financial ratios.

Explore

Watchlists

Command Palette